The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein dipalmitoylphosphatidic acid inhibits the reaction [1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein]
[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid]
[Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Sarin results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Soman results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [VX results in decreased activity of ACHE protein]
MGMT protein mutant form results in decreased susceptibility to Carmustine; MGMT protein results in decreased susceptibility to Carmustine MGMT protein mutant form results in decreased susceptibility to [Carmustine co-treated with O(6)-benzylguanine]
dipalmitoylphosphatidic acid inhibits the reaction [1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein] dipalmitoylphosphatidic acid results in increased activity of PLCG1 protein
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 protein]
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK1 protein]
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK3 protein]
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK8 protein]
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK9 protein]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of ACTA2 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein] ochratoxin A results in increased expression of ACTA2 mRNA; ochratoxin A results in increased expression of ACTA2 protein
ochratoxin A results in increased expression of TGFB1 mRNA; ochratoxin A results in increased expression of TGFB1 protein CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of TGFB1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein] ochratoxin A results in increased expression of GSDMD mRNA; ochratoxin A results in increased expression of GSDMD protein
CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL18 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL1B mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein] ochratoxin A results in increased expression of IL1B mRNA; ochratoxin A results in increased expression of IL1B protein
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of CASP1 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of VIM protein] ochratoxin A results in increased expression of NLRP3 mRNA; ochratoxin A results in increased expression of NLRP3 protein
ochratoxin A results in increased expression of PYCARD mRNA; ochratoxin A results in increased expression of PYCARD protein N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD protein]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of VIM protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of VIM protein] ochratoxin A results in increased expression of VIM mRNA; ochratoxin A results in increased expression of VIM protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; [Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK1 protein; [Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; [Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; [Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK3 protein
Tetradecanoylphorbol Acetate promotes the reaction [Monensin affects the localization of SLC6A9 protein] Tetradecanoylphorbol Acetate affects the localization of SLC6A9 protein
[2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to prochloraz; [prochloraz binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein; [salicylamide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to prochloraz
allicin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; hypericin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; kaempferol inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; Quercetin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]
[Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Sarin results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Soman results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [VX results in decreased activity of ACHE protein]
[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid; [Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP]